Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3
3(100.0%)
3Total
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07637734Phase 3Not Yet Recruiting

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

Role: collaborator

NCT07457918Phase 3Recruiting

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

Role: collaborator

NCT07246590Phase 3Recruiting

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

Role: collaborator

All 3 trials loaded